Seek Returns

BBIO vs. MTD: BridgeBio Pharma vs. Mettler-Toledo Stock Comparison

How do BridgeBio Pharma (BBIO) and Mettler-Toledo (MTD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

BridgeBio Pharma (BBIO) and Mettler-Toledo (MTD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BBIO is classified in Biotechnology while MTD is classified in Life Sciences Tools & Services.

Company profile comparison for BridgeBio Pharma (BBIO) and Mettler-Toledo (MTD)
Profile ItemBBIOMTD
NameBridgeBio Pharma Inc.Mettler-Toledo International Inc.
Country/RegionUnited StatesSwitzerland
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyLife Sciences Tools & Services
GICS Sub-IndustryBiotechnologyLife Sciences Tools & Services
Market Capitalization14.47 billion USD34.25 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateJune 27, 2019November 14, 1997
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

BBIO
MTD
GSPC
Loading price history…
BridgeBio Pharma (BBIO) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for BridgeBio Pharma (BBIO) and Mettler-Toledo (MTD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for BridgeBio Pharma (BBIO) and Mettler-Toledo (MTD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for BridgeBio Pharma (BBIO) and Mettler-Toledo (MTD)
MetricBBIOMTD
Total Return (1Y)22.70%21.58%
Total Return (3Y, Annualized)40.97%19.54%
Total Return (5Y, Annualized)8.25%2.36%

Risk Profile

Drawdown History

BBIO
MTD
GSPC
Loading price history…
BridgeBio Pharma (BBIO) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for BridgeBio Pharma (BBIO) and Mettler-Toledo (MTD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for BridgeBio Pharma (BBIO) and Mettler-Toledo (MTD)
MetricBBIOMTD
Volatility (1Y, Annualized)44.39%31.70%
Beta (5Y)0.931.15
Max Drawdown (5Y)-89.79%-43.47%
Avg. Volume (3M)2.68M197.80K

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BBIO and MTD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for BridgeBio Pharma (BBIO) and Mettler-Toledo (MTD)
MetricBBIOMTD
Sharpe Ratio (1Y)0.410.55
Sortino Ratio (1Y)0.630.75

Profitability

ROE (TTM)

Neither BridgeBio Pharma (BBIO) nor Mettler-Toledo (MTD) reports a ROE value for this period, so a direct comparison isn’t possible.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
BBIO
--

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
MTD
--
Loading chart…
BridgeBio Pharma (BBIO) vs. Mettler-Toledo (MTD): Neither stock reports ROE, so the chart shows available benchmark boxes without value markers.

Net Margin (TTM)

BridgeBio Pharma (BBIO) reports a negative net margin of -59.84%, usually indicating a net loss over the period. Meanwhile Mettler-Toledo (MTD) reports 22.25%, ranking against industry peers normally.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-59.84%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
BBIO
-59.84%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.25%

MTD
22.25%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
BridgeBio Pharma (BBIO) vs. Mettler-Toledo (MTD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

BridgeBio Pharma (BBIO) reports a negative operating margin of -3.30%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Mettler-Toledo (MTD) reports 28.70%, ranking against industry peers normally.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-3.30%

Max
83.12%
Q3
14.77%
Median
0.00%
BBIO
-3.30%
Q1
-78.82%
Min
-207.40%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.70%

Max
83.12%
MTD
28.70%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
BridgeBio Pharma (BBIO) vs. Mettler-Toledo (MTD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for BridgeBio Pharma (BBIO) and Mettler-Toledo (MTD)
MetricBBIOMTD
ROE (TTM)----
ROA (TTM)-13.97%20.09%
Net Margin (TTM)-59.84%22.25%
Operating Margin (TTM)-3.30%28.70%
Gross Margin (TTM)94.34%59.16%

Growth

Revenue Growth

BridgeBio Pharma (BBIO) at 126.26% sits in the top revenue growth quartile, while Mettler-Toledo (MTD) at 3.98% is closer to the peer norm — faster top-line expansion for BBIO.

Loading chart…
BridgeBio Pharma (BBIO) vs. Mettler-Toledo (MTD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Mettler-Toledo (MTD) reports EPS growth of 3.88%, ranked against its industry; BridgeBio Pharma (BBIO) has no EPS growth figure this period.

Loading chart…
BridgeBio Pharma (BBIO) vs. Mettler-Toledo (MTD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for BridgeBio Pharma (BBIO) and Mettler-Toledo (MTD)
MetricBBIOMTD
Revenue Growth (YoY)126.26%3.98%
Revenue Growth (3Y CAGR)86.30%0.90%
EPS Growth (YoY)--3.88%
EPS Growth (3Y CAGR)--3.06%

Financial Strength

Current Ratio (MRQ)

Both BridgeBio Pharma (BBIO) at 2.09 and Mettler-Toledo (MTD) at 1.10 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.09

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
BBIO
2.09
Min
0.10

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.10

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
MTD
1.10
Min
0.10
Loading chart…
BridgeBio Pharma (BBIO) vs. Mettler-Toledo (MTD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Mettler-Toledo (MTD) carries debt-to-equity ratio of 26.06 against its industry range, while BridgeBio Pharma (BBIO) reports no figure this period.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
BBIO
--

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.06

MTD
26.06
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
BridgeBio Pharma (BBIO) vs. Mettler-Toledo (MTD): BBIO does not report debt-to-equity ratio, so it has no value marker; MTD is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for BridgeBio Pharma (BBIO) and Mettler-Toledo (MTD)
MetricBBIOMTD
Current Ratio (MRQ)2.091.10
Debt / Equity (MRQ)--26.06
Net Debt / EBITDA--1.58

Dividends

Dividend Yield (TTM)

Neither BridgeBio Pharma (BBIO) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BBIO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
BridgeBio Pharma (BBIO) vs. Mettler-Toledo (MTD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither BridgeBio Pharma (BBIO) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BBIO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
BridgeBio Pharma (BBIO) vs. Mettler-Toledo (MTD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for BridgeBio Pharma (BBIO) and Mettler-Toledo (MTD)
MetricBBIOMTD
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Mettler-Toledo (MTD) trades at 37.38 times trailing earnings, ranked against its peers, while BridgeBio Pharma (BBIO) has no P/E ratio this period.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
BBIO
--

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.38

Max
85.34
Q3
43.46
MTD
37.38
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
BridgeBio Pharma (BBIO) vs. Mettler-Toledo (MTD): BBIO does not report P/E ratio, so it has no value marker; MTD is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both BridgeBio Pharma (BBIO) at 15.31 and Mettler-Toledo (MTD) at 8.16 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.31

Max
58.18
Q3
25.77
BBIO
15.31
Median
7.30
Q1
3.01
Min
0.01

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.16

Max
58.18
Q3
25.77
MTD
8.16
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
BridgeBio Pharma (BBIO) vs. Mettler-Toledo (MTD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

BridgeBio Pharma (BBIO) reports a negative P/B ratio of -5.59, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Mettler-Toledo (MTD) reports 442.71, ranking against industry peers normally.

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-5.59

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BBIO
-5.59
Min
-5.59

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

442.71

MTD
442.71
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
BridgeBio Pharma (BBIO) vs. Mettler-Toledo (MTD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for BridgeBio Pharma (BBIO) and Mettler-Toledo (MTD)
MetricBBIOMTD
P/E Ratio (TTM)--37.38
P/S Ratio (TTM)15.318.16
P/B Ratio (MRQ)-5.59442.71
Free Cash Flow Yield (TTM)-1.98%1.97%